Page 40 - Read Online

Page 12 of 15 D'Souza et al. J Cancer Metastasis Treat 2022;8:28 https://dx.doi.org/10.20517/2394-4722.2022.51

4. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
(CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. DOI PubMed
5. Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res 2018;7:537-42. DOI PubMed PMC
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone
in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. DOI
7. Kindler HL, Ismaila N, Armato SG, et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology
clinical practice guideline. J Clin Oncol 2018;36:1343-73. DOI
8. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin
Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405-14. DOI
9. Neumann V, Günther S, Müller KM, Fischer M. Malignant mesothelioma - German mesothelioma register 1987-1999. Int Arch
Occup Environ Health 2001;74:383-95. DOI
10. Tracey EKT, Dobrovic A, Currow D. Cancer in NSW: incidence and mortality report 2008. Sydney: Cancer Institute NSW, 2010.
11. Tano ZE, Chintala NK, Li X, Adusumilli PS. Novel immunotherapy clinical trials in malignant pleural mesothelioma. Ann Transl
Med 2017;5:245. DOI PubMed PMC
12. Rijavec E, Biello F, Barletta G, Dellepiane C, Genova C. Novel approaches for the treatment of unresectable malignant pleural
mesothelioma: a focus on immunotherapy and target therapy (Review). Mol Clin Oncol 2022;16:89. DOI PubMed PMC
13. Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Curr Opin Immunol 2018;51:103-10. DOI PubMed PMC
14. Albelda SM. Tumor antigen heterogeneity: the “Elephant in the Room” of adoptive T-cell therapy for solid tumors. Cancer Immunol
Res 2020;8:2. DOI PubMed
15. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest
Oncology Group Study. J Clin Oncol 2007;25:2406-13. DOI PubMed
16. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and
Leukemia Group B. Clin Cancer Res 2005;11:2300-4. DOI PubMed
17. Ou WB, Hubert C, Corson JM, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia
2011;13:12-22. DOI PubMed PMC
18. Ou SH, Moon J, Garland LL, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant
pleural mesothelioma (MPM). J Thorac Oncol 2015;10:387-91. DOI PubMed PMC
19. Avelumab in metastatic or locally advanced solid tumors (JAVELIN solid tumor). Available from:
https://ClinicalTrials.gov/show/NCT01772004 [Last accessed on 21 July 2022].
20. Gounant V, Brosseau S, Zalcman G. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM)
treatment. Ther Adv Med Oncol 2021;13:17588359211061956. DOI PubMed PMC
21. Brockwell NK, Alamgeer M, Kumar B, Rivalland G, John T, Parker BS. Preliminary study highlights the potential of immune
checkpoint inhibitors in sarcomatoid mesothelioma. Transl Lung Cancer Res 2020;9:639-45. DOI PubMed PMC
22. Zalcman G, Mazieres J, Greillier L, et al. Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma:
long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) Ann Oncol 2019. p. v747. DOI
23. Pagano M, Ceresoli GL, Zucali PA, et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line
treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study JCO 2020. p. 9004.
24. Toyokawa G, Takenoyama M, Hirai F, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with
malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014;19:601-6.
25. Tourkantonis I, Makrilia N, Ralli M, et al. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural
mesothelioma: a single institution study. Am J Clin Oncol 2011;34:38-42. DOI
26. Kim RY, Li Y, Marmarelis ME, Vachani A. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus
chemotherapy for malignant pleural mesothelioma. Lung Cancer 2021;159:107-10. DOI PubMed PMC
27. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-
agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-
15) PROMISE-meso trial. Ann Oncol 2020;31:1734-45. DOI PubMed
28. Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most
cancers. JCI Insight 2019;4:126908. DOI PubMed PMC
29. Raghav K, Liu S, Overman MJ, et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF
(Bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov 2021;11:2738-47. DOI PubMed PMC
30. Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial watch: adoptively transferred cells for anticancer
immunotherapy. Oncoimmunology 2017;6:e1363139. DOI PubMed PMC
31. Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol 2018;36:215-9. DOI PubMed
32. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98. DOI
PubMed PMC
33. Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-
specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol
Immunother 2017;66:1425-36. DOI PubMed PMC